Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin B. Klee Sells 7,471 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin B. Klee sold 7,471 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the sale, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ AMLX opened at $3.77 on Thursday. The company has a market capitalization of $258.43 million, a PE ratio of -0.99 and a beta of -0.53. The stock’s 50 day moving average price is $4.90 and its 200-day moving average price is $3.44. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95.

Analyst Ratings Changes

AMLX has been the subject of a number of recent research reports. Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $4.20 to $10.00 in a research report on Wednesday, October 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Finally, Leerink Partners set a $4.00 target price on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a report on Friday, October 18th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its position in shares of Amylyx Pharmaceuticals by 88.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 28,785 shares of the company’s stock valued at $55,000 after purchasing an additional 13,509 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Amylyx Pharmaceuticals during the second quarter worth about $2,300,000. Renaissance Technologies LLC increased its holdings in Amylyx Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 811,488 shares of the company’s stock worth $1,542,000 after buying an additional 106,888 shares during the last quarter. Hsbc Holdings PLC increased its holdings in Amylyx Pharmaceuticals by 57.9% during the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after buying an additional 27,954 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Amylyx Pharmaceuticals in the second quarter worth about $400,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.